|
Novartis Eyes Job Cuts, Plans for $1.22 Billion Hit on Pipeline, Patent Setbacks
Novartis is looking to job cuts and charges of $1.22 billion to help it weather withering revenues from the coming patent loss of blockbuster hypertension drug Diovan and possible slashed sales of Tekturna, which performed poorly in a recent clinical trial.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives